OH-ENOSIX
16.5.2023 15:01:33 CEST | Business Wire | Press release
enosix, Inc., the leading technology provider of real-time, prebuilt SAP data integration solutions, announced the successful completion of its $10 million growth financing led by MK Capital. enosix will use the proceeds to accelerate the development and expansion of its SAP integration platform, while expanding its support of Salesforce, MuleSoft, and ServiceNow clients.
enosix is the proven, SAP data integration approach that is relied upon by leading global manufacturers including recent customer additions, Prevost, a member of Volvo Group, Tremco Inc., and Carl Zeiss AG. enosix empowers SAP ERP customers with the critical last mile of integration in real-time, boosting digital transformation efforts by eliminating error-prone, latent, swivel-chair data entry between systems. enosix uplevels data accuracy, automation and business agility in areas such as, but not limited to, sales quoting, IT asset management, business supply-chain management, B2B eCommerce, and more, allowing for greater utilization of business and SAP skilled resources. These advantages translate to a superior customer experience and greater revenue growth.
“Over the past 30 years we have performed detailed due diligence on hundreds of technology companies,” noted Mark Koulogeorge of MK Capital.“ We have never had a company score higher on product quality and reliability than enosix. The product’s high performance over millions of transactions differentiates enosix from its competitors.”
Jamie Bedard, CEO of SAPinsider observed,“The enterprise landscape for SAP customers continues to become more complex. The accelerated adoption of cloud-based solutions as a result of the global pandemic has only added to this complexity. enosix’s unique approach to real-time, virtualized SAP integration triggers a huge sigh of relief by the SAP industry and offers a potential safety net for tens of thousands of enterprise SAP ERP customers who are not only behind in their S/4HANA migration projects, but those who are trying to keep up with the business demands of digital transformation but don’t have the time, resources, or skilled SAP talent available to support a major traditional integration project.”
Nick Fera, CEO of enosix noted “The increasing demand for pre-built, real-time, bi-directional access to legacy ERP solutions, especially during these difficult economic times, positions enosix for tremendous growth. Companies are tired of paying millions to systems integrators for bespoke integration solutions that offer only synchronous experience and require long-term maintenance. The ability to ‘have a two-way conversation’ with your legacy ERP solutions is no longer a dream, enosix has delivered a platform to handle complex pricing and quoting and is now better positioned to expand.”
About enosix, Inc
enosix is the standard for real-time, prebuilt SAP ERP integration. enosix provides real-time data virtualization, which enables a more agile and compliant customer experience by reducing error-prone data entry and information delays. enosix seamlessly connects SAP ECC and S/4HANA systems to modern front-end systems such as Saleforce, MuleSoft, ServiceNow to support rapid digital transformation. The enosix platform leverages low or no-code Packaged Integration Processes (PIP) so companies can quickly realize value—in weeks instead of months. enosix' use of data virtualization unlocks data, business processes, authorizations, and user permissions from SAP without recreating them from the front-end; delivering the back-end translation in an easy-to-understand, real-time, and bi-directional integration. For more information, visit www.enosix.com
About MK Capital
MK Capital is an early-stage lead investor in the software and cloud services industries. The firm's partners, who average more than 20 years of venture capital experience, actively partner with entrepreneurial management teams to build leading companies that accelerate the digital transformation of the global economy. MK Capital manages over $400 million in capital and is actively seeking new investment opportunities. For more information, visit www.mkcapital.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom